Comparative Pharmacology
Head-to-head clinical analysis: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER versus PROPRANOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER versus PROPRANOLOL HYDROCHLORIDE.
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER vs PROPRANOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Non-selective beta-adrenergic receptor antagonist that blocks catecholamine effects at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure; also suppresses renin release and decreases sympathetic outflow.
Intravenous: For stable patients, an initial loading dose of 500 mcg/kg/min over 1 minute followed by a maintenance infusion of 50 mcg/kg/min for 4 minutes; if response is inadequate, increase maintenance infusion to 100 mcg/kg/min and repeat loading dose after 10 minutes. Titrate in 50 mcg/kg/min increments up to 200 mcg/kg/min. For intraoperative and postoperative use, see full prescribing information.
Adults: 40 mg orally twice daily, increased gradually to 160-320 mg/day divided into 2-3 doses; maximum 640 mg/day. For hypertension: 80 mg orally twice daily, titrated to 120-240 mg/day. For migraine prophylaxis: 80 mg orally daily in divided doses, up to 160-240 mg/day. For angina: 80-320 mg orally divided into 2-4 doses. For essential tremor: 40 mg orally twice daily, up to 320 mg/day. For thyrotoxicosis: 10-40 mg orally every 6 hours. For IV use: 1-3 mg slow IV bolus (1 mg/min), repeated every 2-5 minutes up to total of 5 mg under continuous monitoring.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes (range 8–10 minutes). Clinically, the half-life is consistent with rapid offset of effect upon discontinuation; steady state is achieved within 30 minutes of continuous infusion.
3-6 hours (terminal half-life), prolonged in hepatic impairment (up to 10-12 hours) and in elderly; half-life ~1-2 hours after IV administration; clinically, twice-daily dosing is sufficient due to sustained pharmacodynamic effect despite short half-life.
Primarily metabolized by red blood cell esterases; <1% excreted unchanged in urine. Elimination is not dependent on renal or hepatic function.
Hepatic metabolism (extensive first-pass) to inactive metabolites; <1% excreted unchanged in urine; renal elimination of metabolites (~90% as glucuronide and sulfate conjugates); biliary/fecal elimination minimal.
Category C
Category C
Beta-Blocker
Beta-Blocker